Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CPHI NASDAQ:NBSE NASDAQ:PPBT NASDAQ:XBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPHIChina Pharma$1.64-4.1%$1.76$1.20▼$3.35$5.35M0.79108,881 shs236,838 shsNBSENeuBase Therapeutics$0.38$0.38$0.36▼$4.80$1.43MN/AN/AN/APPBTPurple Biotech$2.17+0.5%$2.46$2.00▼$13.95$5.61M0.49263,223 shs30,777 shsXBIOXenetic Biosciences$3.20-1.2%$3.38$2.20▼$5.27$4.96M2.3252,563 shs21,332 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPHIChina Pharma0.00%-13.87%-10.87%-14.14%-91.72%NBSENeuBase Therapeutics0.00%0.00%0.00%0.00%0.00%PPBTPurple Biotech0.00%-6.87%-12.99%-6.47%+216,999,900.00%XBIOXenetic Biosciences0.00%-11.21%-13.13%+14.53%-25.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPHIChina PharmaN/AN/AN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APPBTPurple Biotech2.2334 of 5 stars3.55.00.00.00.60.00.6XBIOXenetic Biosciences0.8695 of 5 stars0.03.00.00.01.50.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPHIChina Pharma 0.00N/AN/AN/ANBSENeuBase Therapeutics 0.00N/AN/AN/APPBTPurple Biotech 3.00Buy$33.001,420.74% UpsideXBIOXenetic Biosciences 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPHIChina Pharma$4.30M1.25N/AN/A$0.70 per share2.34NBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/A$12.73 per shareN/AXBIOXenetic Biosciences$2.50M1.97N/AN/A$3.89 per share0.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPHIChina Pharma-$3.08MN/A0.00∞N/A-85.56%-63.93%-31.42%N/ANBSENeuBase Therapeutics-$4.37MN/A0.00∞N/AN/AN/AN/AN/APPBTPurple Biotech-$7.24M-$2.62N/AN/AN/AN/A-17.84%-15.44%8/15/2025 (Estimated)XBIOXenetic Biosciences-$3.96M-$2.38N/AN/AN/A-142.10%-57.31%-49.30%8/12/2025 (Estimated)Latest NBSE, CPHI, PPBT, and XBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/15/2025N/APPBTPurple Biotech-$0.21N/AN/AN/AN/AN/A8/12/2025Q2 2025XBIOXenetic Biosciences-$0.64N/AN/AN/A$0.48 millionN/A5/21/2025Q1 2025PPBTPurple BiotechN/A-$0.17N/A-$0.17N/AN/A5/13/2025Q1 2025XBIOXenetic Biosciences-$0.72-$0.59+$0.13-$0.59$0.52 million$0.59 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPHIChina PharmaN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/APPBTPurple BiotechN/AN/AN/AN/AN/AXBIOXenetic BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPHIChina Pharma0.220.790.26NBSENeuBase TherapeuticsN/AN/AN/APPBTPurple BiotechN/A2.722.72XBIOXenetic BiosciencesN/A8.208.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPHIChina PharmaN/ANBSENeuBase Therapeutics12.37%PPBTPurple Biotech9.64%XBIOXenetic Biosciences15.12%Insider OwnershipCompanyInsider OwnershipCPHIChina Pharma17.32%NBSENeuBase Therapeutics7.90%PPBTPurple Biotech2.98%XBIOXenetic Biosciences14.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPHIChina Pharma2503.26 million15.92 millionNot OptionableNBSENeuBase Therapeutics403.75 million3.46 millionNot OptionablePPBTPurple Biotech202.59 million2.51 millionOptionableXBIOXenetic Biosciences41.54 million1.32 millionNot OptionableNBSE, CPHI, PPBT, and XBIO HeadlinesRecent News About These CompaniesXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell LymphomaJuly 30, 2025 | accessnewswire.comAXenetic Biosciences expands R&D collaboration with The Scripps Research Institute to advance DNase platformJuly 26, 2025 | pharmabiz.comPXenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformJuly 23, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the ...July 8, 2025 | finanznachrichten.deXenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic CancerJuly 8, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 14, 2025 | accessnewswire.comAXenetic Biosciences (XBIO) Receives a Hold from H.C. WainwrightApril 9, 2025 | markets.businessinsider.comXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentApril 9, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing SarcomaMarch 26, 2025 | accessnewswire.comAXenetic Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS LagsMarch 20, 2025 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2024 Financial ResultsMarch 19, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic ResponsesMarch 13, 2025 | accessnewswire.comAXenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy MeetingFebruary 27, 2025 | accessnewswire.comAXenetic Biosciences extends research agreement with University of Virginia for the advancement of its DNase-based oncology platformDecember 18, 2024 | pharmabiz.comPXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentDecember 17, 2024 | accesswire.comAXenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology PlatformDecember 16, 2024 | accesswire.comAXenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology ProgramDecember 5, 2024 | accesswire.comAXenetic Biosciences, Inc. Releases Virtual Investor "What This Means" SegmentNovember 22, 2024 | accesswire.comAXenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung MetastasisNovember 21, 2024 | accesswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBSE, CPHI, PPBT, and XBIO Company DescriptionsChina Pharma NYSE:CPHI$1.64 -0.07 (-4.09%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$1.66 +0.02 (+1.28%) As of 08/1/2025 06:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. In addition, the company provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. Further it offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It offers its products through distributors, its network of sales offices, and sales representatives. The company is based in Haikou, the People's Republic of China.NeuBase Therapeutics NASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.Purple Biotech NASDAQ:PPBT$2.17 +0.01 (+0.46%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.15 -0.02 (-1.11%) As of 08/1/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Xenetic Biosciences NASDAQ:XBIO$3.20 -0.04 (-1.20%) As of 08/1/2025 03:55 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
